Drug Profile
Research programme: BCL2 family protein inhibitors - Asinex
Alternative Names: ASNX-BCLLatest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator ASINEX
- Class Antineoplastics
- Mechanism of Action Bcl-X protein inhibitors; MCL1 protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Haematological-malignancies in USA
- 28 Aug 2020 No recent reports of development identified for research development in Solid-tumours in USA
- 12 Jul 2016 Research programme: BCL2 family protein inhibitors - Asinex is available for licensing as of 12 Jul 2016. http://www.asinex.com/